Physician profile
Kari E Wolf
NPI 1952974859
$4,295.97
in general payments reported to CMS, 2019-2025
36 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $1,341 · 2023: $664 · 2024: $958 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,714.03 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $464.21 | 2024-2025 | |
| Ucb, INC. | $383.28 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $275.40 | 2022-2024 | Sotyktu, Camzyos |
| Sun Pharmaceutical Industries INC. | $272.09 | 2024-2025 | |
| Abbott Laboratories | $244.02 | 2022-2023 | Cardiomems |
| Alnylam Pharmaceuticals INC. | $219.32 | 2021-2023 | Onpattro |
| Incyte Corporation | $218.58 | 2024-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $180.85 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $169.04 | 2022-2023 | Lifevest |
| Genzyme Corporation | $168.24 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.81 | 2022 | |
| Lilly USA, LLC | $156.69 | 2024-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Pharmaceuticals, INC | $151.42 | 2022-2023 | Xarelto |
| Pfizer INC. | $117.09 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.70 | 2022-2024 | Spevigo, Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $96.44 | 2022-2025 | Otezla, Otezla, Repatha |
| Janssen Biotech, INC. | $92.11 | 2024-2025 | Tremfya |
| Astrazeneca Pharmaceuticals Lp | $90.67 | 2022-2023 | Andexxa |
| Merck Sharp & Dohme LLC | $90.53 | 2021-2023 | Verquvo |
| Boston Scientific Corporation | $82.57 | 2022-2023 | Watchman Access System, Watchman |
| Abiomed | $81.06 | 2021 | |
| Daiichi Sankyo INC. | $68.38 | 2022-2023 | Injectafer |
| Actelion Pharmaceuticals US, INC. | $66.13 | 2023 | Opsumit, Uptravi |
| Leo Pharma INC. | $51.07 | 2025 | Adbry |
| Kiniksa Pharmaceuticals, Ltd. | $37.73 | 2022 | |
| Convatec INC. | $34.43 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $34.11 | 2023 | Evkeeza |
| Lexicon Pharmaceuticals, INC. | $32.30 | 2023 | Inpefa |
| Medtronic, INC. | $31.95 | 2022 | |
| Cmp Pharma, INC. | $23.06 | 2022 | |
| Janssen Scientific Affairs, LLC | $18.46 | 2024 | Tremfya |
| Organogenesis INC. | $14.47 | 2024 | |
| Livanova USA, INC. | $14.39 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.60 | 2024 | Siliq |
| Scpharmaceuticals INC. | $13.40 | 2023 | |
| Organon LLC | $9.37 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kari Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.